amifostine anhydrous and Mucositis studies

Amifostine: A phosphorothioate proposed as a radiation-protective agent. It causes splenic vasodilation and may block autonomic ganglia.
amifostine : An organic thiophosphate that is the S-phospho derivative of 2-[(3-aminopropyl)amino]ethanethiol. A prodrug for the free thiol, WR-1065, which is used as a cytoprotectant in cancer chemotherapy and radiotherapy.

Mucositis: An INFLAMMATION of the MUCOSA with burning or tingling sensation. It is characterized by atrophy of the squamous EPITHELIUM, vascular damage, inflammatory infiltration, and ulceration. It usually occurs at the mucous lining of the MOUTH, the GASTROINTESTINAL TRACT or the airway due to chemical irritations, CHEMOTHERAPY, or radiation therapy (RADIOTHERAPY).

Research Excerpts

Excerpt	Relevance	Reference
"Amifostine has been shown to be capable of minimizing radiotherapy-induced oral mucositis, but whether it protects small intestinal mucosae from high-dose methotrexate-induced damage is presently unknown."	7.79	Protective effect of amifostine on high-dose methotrexate-induced small intestinal mucositis in mice. ( Cao, X; Chen, C; Hao, L; Li, X; Liu, Q; Sun, Q; Tian, L; Zhang, M; Zhang, X, 2013)
"With the eventual goal of reducing relapse and thus improving overall survival in selected lymphoma patients, a Phase I study was performed using the cytoprotectant amifostine to permit safe dose-augmentation of melphalan in the carmustine (BCNU), etoposide, cytarabine (arabinosylcytosine), and melphalan (BEAM) regimen before autologous hematopoietic stem cell transplantation."	5.15	A Phase I trial: dose escalation of melphalan in the "BEAM" regimen using amifostine cytoprotection. ( Abboud, CN; Becker, MW; Bernstein, SH; Constine, LS; Friedberg, JW; Ifthikharuddin, JJ; Liesveld, JL; Loughner, JE; Milner, LA; Phillips, GL; Vesole, DH, 2011)
"Amifostine has been shown to be capable of minimizing radiotherapy-induced oral mucositis, but whether it protects small intestinal mucosae from high-dose methotrexate-induced damage is presently unknown."	3.79	Protective effect of amifostine on high-dose methotrexate-induced small intestinal mucositis in mice. ( Cao, X; Chen, C; Hao, L; Li, X; Liu, Q; Sun, Q; Tian, L; Zhang, M; Zhang, X, 2013)
" There were no reports of Grade >/=3 amifostine-related adverse events."	2.73	Efficacy and safety of subcutaneous amifostine in minimizing radiation-induced toxicities in patients receiving combined-modality treatment for squamous cell carcinoma of the head and neck. ( Christie, D; Kennedy, T; Law, A; Pellitteri, P; Wood, C; Yumen, O, 2007)
"Radiation-induced mucositis is a common toxicity, especially in patients with head and neck cancers."	2.58	Pharmacological modulation of radiation-induced oral mucosal complications. ( Annede, P; Blanchard, P; Bockel, S; Bourdis, M; Chargari, C; Deutsch, É; Drouet, M; François, S; Le Gallic, C; Lévy, A; Magné, N; Riccobono, D; Tao, Y; Vallard, A, 2018)
"Mucositis is a highly significant, and sometimes dose-limiting, toxicity of cancer therapy."	2.50	MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. ( Barasch, A; Bowen, J; Elad, S; Elting, L; Epstein, J; Keefe, DM; Lalla, RV; McGuire, DB; Migliorati, C; Nicolatou-Galitis, O; Peterson, DE; Raber-Durlacher, JE; Sonis, ST, 2014)
"Nearly two thirds of all patients with cancer receive radiation therapy during the course of treatment, frequently resulting in acute skin and mucosal toxicities."	2.49	Prevention and management of radiation-induced dermatitis, mucositis, and xerostomia. ( Pace, MB; Radvansky, LJ; Siddiqui, A, 2013)
"Current standard treatments for cancer are associated with major dose-limiting toxic effects on healthy tissue."	2.44	Prevention and treatment of regimen-related mucosal toxicity. ( Bowen, JM, 2008)
"The pathobiology of mucositis is complex, and agents that target mechanisms to prevent mucositis or accelerate healing are in high demand."	2.44	Emerging drugs for chemotherapy-induced mucositis. ( Bowen, JM; Keefe, DM; Sonis, ST, 2008)
"Radiation for head and neck cancers is often curative, but high doses are used."	2.43	How to reduce radiation-related toxicity in patients with cancer of the head and neck. ( Chambers, MS; Garden, AS; Lewin, JS, 2006)
"Mucositis is a significant complication of cancer therapy, with important clinical and economic implications."	2.43	Amifostine in the management of radiation-induced and chemo-induced mucositis. ( Bensadoun, RJ; Keefe, D; Lalla, RV; Schubert, MM, 2006)
"Mucositis was scored by either the WHO, the National Cancer Institute-Common Toxicity Criteria (NCI-CTC) score, or the absence or presence of ulcerations, or the presence or absence of grades 3 and 4 mucositis."	2.43	Preventive intervention possibilities in radiotherapy- and chemotherapy-induced oral mucositis: results of meta-analyses. ( Boezen, HM; de Vries, EG; Roodenburg, JL; Schouten, JP; Spijkervet, FK; Stokman, MA, 2006)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	7 (53.85)	29.6817
2010's	6 (46.15)	24.3611
2020's	0 (0.00)	2.80

Trial	Phase	Enrollment	Study Type	Start Date	Status
A Randomized Study of a New Medical Device for Oral Mucositis (MDOM Trial)[NCT05104268]	Phase 1/Phase 2	100 participants (Anticipated)	Interventional	2021-11-30	Not yet recruiting
Low Power Laser Therapy As Prevention Of Oral Mucositis And Oropharyngeal Pain In Patients Undergoing Allogenetic Hematopoietic Stem Cell Transplantation.[NCT06071637]	Phase 3	84 participants (Anticipated)	Interventional	2023-08-01	Recruiting
Cryoprotection of Chemotherapy-induced Oral Mucositis After Autologous Stem Cell Transplantation, a Randomized Study[NCT03203733]		182 participants (Actual)	Interventional	2017-06-12	Completed
A Phase 1/Phase 2 Study for the Prevention of Oral Mucositis (SPOM)[NCT05338398]	Phase 1/Phase 2	100 participants (Anticipated)	Interventional	2022-04-15	Enrolling by invitation
Opioid Therapy vs Multimodal Analgesia in Head and Neck Cancer: A Randomized Clinical Trial[NCT04221165]	Phase 2	62 participants (Anticipated)	Interventional	2020-08-04	Recruiting
Phase I Study of Multiple Ascending Dose, to Investigate the Safety and Tolerability of the Use of Copaiba in Patients With Oral Cancer Submitted to Radiotherapy[NCT05308732]	Phase 1	36 participants (Anticipated)	Interventional	2021-05-11	Recruiting
Impacts of Oral Supplement With L-Glutamine on the Radiation-induced Toxicity and Nutritional Status of Head and Neck Cancer Patients Under Radiotherapy[NCT03015077]		59 participants (Actual)	Interventional	2014-07-31	Completed
A Phase III Study of Magic Mouthwash Plus Sucralfate Versus Benzydamine HCl for Treatment of Radiation-induced Oral Mucositis in Head and Neck Cancer Patients.[NCT00814359]	Phase 3	67 participants (Actual)	Interventional	2009-05-31	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Article	Year
Pharmacological modulation of radiation-induced oral mucosal complications. Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique, 2018, Volume: 22, Issue:5 Topics: Amifostine; Analgesics; Anti-Inflammatory Agents; Benzydamine; Dietary Supplements; Fibroblast Growt	2018
Prevention and management of radiation-induced dermatitis, mucositis, and xerostomia. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2013, Jun-15, Volume: 70, Issue:12 Topics: Administration, Topical; Amifostine; Analgesics; Antineoplastic Protocols; Combined Modality Therapy	2013
MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. Cancer, 2014, May-15, Volume: 120, Issue:10 Topics: Amifostine; Analgesics; Anti-Infective Agents; Anti-Inflammatory Agents; Anti-Ulcer Agents; Antineop	2014
MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. Cancer, 2014, May-15, Volume: 120, Issue:10 Topics: Amifostine; Analgesics; Anti-Infective Agents; Anti-Inflammatory Agents; Anti-Ulcer Agents; Antineop	2014
MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. Cancer, 2014, May-15, Volume: 120, Issue:10 Topics: Amifostine; Analgesics; Anti-Infective Agents; Anti-Inflammatory Agents; Anti-Ulcer Agents; Antineop	2014
MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. Cancer, 2014, May-15, Volume: 120, Issue:10 Topics: Amifostine; Analgesics; Anti-Infective Agents; Anti-Inflammatory Agents; Anti-Ulcer Agents; Antineop	2014
MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. Cancer, 2014, May-15, Volume: 120, Issue:10 Topics: Amifostine; Analgesics; Anti-Infective Agents; Anti-Inflammatory Agents; Anti-Ulcer Agents; Antineop	2014
MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. Cancer, 2014, May-15, Volume: 120, Issue:10 Topics: Amifostine; Analgesics; Anti-Infective Agents; Anti-Inflammatory Agents; Anti-Ulcer Agents; Antineop	2014
MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. Cancer, 2014, May-15, Volume: 120, Issue:10 Topics: Amifostine; Analgesics; Anti-Infective Agents; Anti-Inflammatory Agents; Anti-Ulcer Agents; Antineop	2014
MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. Cancer, 2014, May-15, Volume: 120, Issue:10 Topics: Amifostine; Analgesics; Anti-Infective Agents; Anti-Inflammatory Agents; Anti-Ulcer Agents; Antineop	2014
MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. Cancer, 2014, May-15, Volume: 120, Issue:10 Topics: Amifostine; Analgesics; Anti-Infective Agents; Anti-Inflammatory Agents; Anti-Ulcer Agents; Antineop	2014
MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. Cancer, 2014, May-15, Volume: 120, Issue:10 Topics: Amifostine; Analgesics; Anti-Infective Agents; Anti-Inflammatory Agents; Anti-Ulcer Agents; Antineop	2014
MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. Cancer, 2014, May-15, Volume: 120, Issue:10 Topics: Amifostine; Analgesics; Anti-Infective Agents; Anti-Inflammatory Agents; Anti-Ulcer Agents; Antineop	2014
MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. Cancer, 2014, May-15, Volume: 120, Issue:10 Topics: Amifostine; Analgesics; Anti-Infective Agents; Anti-Inflammatory Agents; Anti-Ulcer Agents; Antineop	2014
MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. Cancer, 2014, May-15, Volume: 120, Issue:10 Topics: Amifostine; Analgesics; Anti-Infective Agents; Anti-Inflammatory Agents; Anti-Ulcer Agents; Antineop	2014
MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. Cancer, 2014, May-15, Volume: 120, Issue:10 Topics: Amifostine; Analgesics; Anti-Infective Agents; Anti-Inflammatory Agents; Anti-Ulcer Agents; Antineop	2014
MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. Cancer, 2014, May-15, Volume: 120, Issue:10 Topics: Amifostine; Analgesics; Anti-Infective Agents; Anti-Inflammatory Agents; Anti-Ulcer Agents; Antineop	2014
MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. Cancer, 2014, May-15, Volume: 120, Issue:10 Topics: Amifostine; Analgesics; Anti-Infective Agents; Anti-Inflammatory Agents; Anti-Ulcer Agents; Antineop	2014
MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. Cancer, 2014, May-15, Volume: 120, Issue:10 Topics: Amifostine; Analgesics; Anti-Infective Agents; Anti-Inflammatory Agents; Anti-Ulcer Agents; Antineop	2014
MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. Cancer, 2014, May-15, Volume: 120, Issue:10 Topics: Amifostine; Analgesics; Anti-Infective Agents; Anti-Inflammatory Agents; Anti-Ulcer Agents; Antineop	2014
MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. Cancer, 2014, May-15, Volume: 120, Issue:10 Topics: Amifostine; Analgesics; Anti-Infective Agents; Anti-Inflammatory Agents; Anti-Ulcer Agents; Antineop	2014
MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. Cancer, 2014, May-15, Volume: 120, Issue:10 Topics: Amifostine; Analgesics; Anti-Infective Agents; Anti-Inflammatory Agents; Anti-Ulcer Agents; Antineop	2014
MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. Cancer, 2014, May-15, Volume: 120, Issue:10 Topics: Amifostine; Analgesics; Anti-Infective Agents; Anti-Inflammatory Agents; Anti-Ulcer Agents; Antineop	2014
MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. Cancer, 2014, May-15, Volume: 120, Issue:10 Topics: Amifostine; Analgesics; Anti-Infective Agents; Anti-Inflammatory Agents; Anti-Ulcer Agents; Antineop	2014
MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. Cancer, 2014, May-15, Volume: 120, Issue:10 Topics: Amifostine; Analgesics; Anti-Infective Agents; Anti-Inflammatory Agents; Anti-Ulcer Agents; Antineop	2014
MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. Cancer, 2014, May-15, Volume: 120, Issue:10 Topics: Amifostine; Analgesics; Anti-Infective Agents; Anti-Inflammatory Agents; Anti-Ulcer Agents; Antineop	2014
MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. Cancer, 2014, May-15, Volume: 120, Issue:10 Topics: Amifostine; Analgesics; Anti-Infective Agents; Anti-Inflammatory Agents; Anti-Ulcer Agents; Antineop	2014
MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. Cancer, 2014, May-15, Volume: 120, Issue:10 Topics: Amifostine; Analgesics; Anti-Infective Agents; Anti-Inflammatory Agents; Anti-Ulcer Agents; Antineop	2014
MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. Cancer, 2014, May-15, Volume: 120, Issue:10 Topics: Amifostine; Analgesics; Anti-Infective Agents; Anti-Inflammatory Agents; Anti-Ulcer Agents; Antineop	2014
MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. Cancer, 2014, May-15, Volume: 120, Issue:10 Topics: Amifostine; Analgesics; Anti-Infective Agents; Anti-Inflammatory Agents; Anti-Ulcer Agents; Antineop	2014
MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. Cancer, 2014, May-15, Volume: 120, Issue:10 Topics: Amifostine; Analgesics; Anti-Infective Agents; Anti-Inflammatory Agents; Anti-Ulcer Agents; Antineop	2014
MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. Cancer, 2014, May-15, Volume: 120, Issue:10 Topics: Amifostine; Analgesics; Anti-Infective Agents; Anti-Inflammatory Agents; Anti-Ulcer Agents; Antineop	2014
MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. Cancer, 2014, May-15, Volume: 120, Issue:10 Topics: Amifostine; Analgesics; Anti-Infective Agents; Anti-Inflammatory Agents; Anti-Ulcer Agents; Antineop	2014
MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. Cancer, 2014, May-15, Volume: 120, Issue:10 Topics: Amifostine; Analgesics; Anti-Infective Agents; Anti-Inflammatory Agents; Anti-Ulcer Agents; Antineop	2014
MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. Cancer, 2014, May-15, Volume: 120, Issue:10 Topics: Amifostine; Analgesics; Anti-Infective Agents; Anti-Inflammatory Agents; Anti-Ulcer Agents; Antineop	2014
MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. Cancer, 2014, May-15, Volume: 120, Issue:10 Topics: Amifostine; Analgesics; Anti-Infective Agents; Anti-Inflammatory Agents; Anti-Ulcer Agents; Antineop	2014
MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. Cancer, 2014, May-15, Volume: 120, Issue:10 Topics: Amifostine; Analgesics; Anti-Infective Agents; Anti-Inflammatory Agents; Anti-Ulcer Agents; Antineop	2014
MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. Cancer, 2014, May-15, Volume: 120, Issue:10 Topics: Amifostine; Analgesics; Anti-Infective Agents; Anti-Inflammatory Agents; Anti-Ulcer Agents; Antineop	2014
Prevention and treatment of regimen-related mucosal toxicity. Recent patents on anti-cancer drug discovery, 2008, Volume: 3, Issue:2 Topics: Amifostine; Animals; Antineoplastic Agents; Apoptosis; Cell Proliferation; Cytoprotection; Humans; I	2008
Emerging drugs for chemotherapy-induced mucositis. Expert opinion on emerging drugs, 2008, Volume: 13, Issue:3 Topics: Acetylcysteine; Amifostine; Antineoplastic Agents; Drugs, Investigational; Fibroblast Growth Factor	2008
How to reduce radiation-related toxicity in patients with cancer of the head and neck. Current oncology reports, 2006, Volume: 8, Issue:2 Topics: Amifostine; Anti-Infective Agents; Deglutition Disorders; Fibrosis; Free Radical Scavengers; Growth	2006
Amifostine in the management of radiation-induced and chemo-induced mucositis. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2006, Volume: 14, Issue:6 Topics: Amifostine; Antineoplastic Agents; Combined Modality Therapy; Esophagitis; Evidence-Based Medicine;	2006
Preventive intervention possibilities in radiotherapy- and chemotherapy-induced oral mucositis: results of meta-analyses. Journal of dental research, 2006, Volume: 85, Issue:8 Topics: Amifostine; Anti-Bacterial Agents; Antineoplastic Agents; Colony-Stimulating Factors; Cranial Irradi	2006
Preventive intervention possibilities in radiotherapy- and chemotherapy-induced oral mucositis: results of meta-analyses. Journal of dental research, 2006, Volume: 85, Issue:8 Topics: Amifostine; Anti-Bacterial Agents; Antineoplastic Agents; Colony-Stimulating Factors; Cranial Irradi	2006
Preventive intervention possibilities in radiotherapy- and chemotherapy-induced oral mucositis: results of meta-analyses. Journal of dental research, 2006, Volume: 85, Issue:8 Topics: Amifostine; Anti-Bacterial Agents; Antineoplastic Agents; Colony-Stimulating Factors; Cranial Irradi	2006
Preventive intervention possibilities in radiotherapy- and chemotherapy-induced oral mucositis: results of meta-analyses. Journal of dental research, 2006, Volume: 85, Issue:8 Topics: Amifostine; Anti-Bacterial Agents; Antineoplastic Agents; Colony-Stimulating Factors; Cranial Irradi	2006
Amifostine: the first selective-target and broad-spectrum radioprotector. The oncologist, 2007, Volume: 12, Issue:6 Topics: Amifostine; Humans; Mucositis; Neoplasms; Radiation-Protective Agents; Radiotherapy; Treatment Outco	2007

Article	Year
Radiochemotherapy with cetuximab, cisplatin, and amifostine for locally advanced head and neck cancer: a feasibility study. International journal of radiation oncology, biology, physics, 2010, May-01, Volume: 77, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Amifostine; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanize	2010
A Phase I trial: dose escalation of melphalan in the "BEAM" regimen using amifostine cytoprotection. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2011, Volume: 17, Issue:7 Topics: Adult; Aged; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Atrial Fibrillation; Carmus	2011
Efficacy and safety of subcutaneous amifostine in minimizing radiation-induced toxicities in patients receiving combined-modality treatment for squamous cell carcinoma of the head and neck. International journal of radiation oncology, biology, physics, 2007, Dec-01, Volume: 69, Issue:5 Topics: Adult; Aged; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squ	2007

amifostine anhydrous and Mucositis

Research Excerpts

Research

Studies (13)

Authors

Clinical Trials (8)

Trial Overview

Reviews

Trials

Other Studies

Authors	Studies
Bockel, S	1
Vallard, A	1
Lévy, A	1
François, S	1
Bourdis, M	1
Le Gallic, C	1
Riccobono, D	1
Annede, P	1
Drouet, M	1
Tao, Y	1
Blanchard, P	1
Deutsch, É	1
Magné, N	1
Chargari, C	1
Radvansky, LJ	1
Pace, MB	1
Siddiqui, A	1
Chen, C	1
Tian, L	1
Zhang, M	1
Sun, Q	1
Zhang, X	1
Li, X	2
Cao, X	1
Liu, Q	1
Hao, L	1
Lalla, RV	2
Bowen, J	1
Barasch, A	1
Elting, L	1
Epstein, J	1
Keefe, DM	2
McGuire, DB	1
Migliorati, C	1
Nicolatou-Galitis, O	1
Peterson, DE	1
Raber-Durlacher, JE	1
Sonis, ST	2
Elad, S	1
Bowen, JM	2
Koukourakis, MI	1
Tsoutsou, PG	1
Karpouzis, A	1
Tsiarkatsi, M	1
Karapantzos, I	1
Daniilidis, V	1
Kouskoukis, C	1
Phillips, GL	1
Bernstein, SH	1
Liesveld, JL	1
Abboud, CN	1
Becker, MW	1
Constine, LS	1
Ifthikharuddin, JJ	1
Loughner, JE	1
Milner, LA	1
Vesole, DH	1
Friedberg, JW	1
Garden, AS	1
Lewin, JS	1
Chambers, MS	1
Bensadoun, RJ	1
Schubert, MM	1
Keefe, D	1
Stokman, MA	1
Spijkervet, FK	1
Boezen, HM	1
Schouten, JP	1
Roodenburg, JL	1
de Vries, EG	1
Kouvaris, JR	1
Kouloulias, VE	1
Vlahos, LJ	1
Law, A	1
Kennedy, T	1
Pellitteri, P	1
Wood, C	1
Christie, D	1
Yumen, O	1